Adoptive Transfer of Haploidentical NK Cells and N-803

Phase 1 Completed 9 enrolled University of Minnesota

NaSingle-groupOpen-labelTreatment

Summary

This is a pilot therapeutic study of related donor HLA-haploidentical NK-cell based therapy to determine if the treatment is safe and well-tolerated and if there is any measureable impact on virus reservoirs.

Timeline

Start: 2019-05-01
Primary completion: 2021-04-01
Completion: 2021-04-01

Publications

Miller JS, Rhein J, Davis ZB, Cooley S, McKenna D, Anderson J, Escandon K, Wieking G, Reichel J, Thorkelson A, Jorstad S, Safrit JT, Soon-Shiong P, Beilman GJ, Chipman JG, Schacker TW. Safety and Virologic Impact of Haploidentical NK Cells Plus Interleukin 2 or N-803 in HIV Infection. J Infect Dis. 2024 May 15;229(5):1256-1265. doi: 10.1093/infdis/jiad578.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Haploidentical Natural Killer (NK) Cells	Cell therapy	—	—
Subject	N-803	Protein / enzyme biologic	—	—

Adoptive Transfer of Haploidentical NK Cells and N-803

Summary

Timeline

Publications

Drugs

Indications